- Research article
- Open Access
- Open Peer Review
Identification of mimotopes of Mycobacterium leprae as potential diagnostic reagents
© Alban et al.; licensee BioMed Central Ltd. 2013
- Received: 8 February 2012
- Accepted: 22 January 2013
- Published: 25 January 2013
An early diagnostic test for detecting infection in leprosy is fundamental for reducing patients’ sequelae. The currently used lepromin is not adequate for disease diagnosis and, so far, no antigen to be used in intradermoreaction has proved to be sensitive and specific for that purpose. Aiming at identifying new reagents to be used in skin tests, candidate antigens were investigated.
Random peptide phage display libraries were screened by using antibodies from leprosy patients in order to identify peptides as diagnostic reagents.
Seven different phage clones were identified using purified antibodies pooled from sera of leprosy patients. When the clones were tested with serum samples by ELISA, three of them, 5A, 6A and 1B, allowed detecting a larger number of leprosy patients when compared to controls. The corresponding peptides expressed by selected phage clones were chemically synthesized. A pilot study was undertaken to assess the use of peptides in skin tests. The intradermal challenge with peptides in animals previously sensitized with Mycobacterium leprae induced a delayed-type hypersensitivity with peptide 5A (2/5) and peptide 1B (1/5). In positive controls, there was a 3/5 reactivity for lepromin and a 4/5 reactivity of the sensitized animals with soluble extract of M. leprae.
The preliminary data suggest that may be possible to develop reagents with diagnostic potential based on peptide mimotopes selected by phage display using polyclonal human antibodies.
- Phage Clone
- Leprosy Patient
- Mycobacterial Antigen
- Lepromatous Leprosy Patient
Leprosy is a chronic granulomatous infectious disease caused by M. leprae that affects the skin and the peripheral nervous system . This disease constitutes a public health problem in countries such as Brazil , where large numbers of patients with sequelae as a result of neural damages are still observed every year . Upon the introduction of multidrug therapy in 1981 by the WHO, the prevalence of leprosy has been dramatically reduced, but over the last 5 years, more than 200,000 new cases have been detected each year . These more recent data indicate that the transmission of leprosy still goes on , which makes it clear that new strategies - besides treatment - are necessary to eliminate the disease as a public health problem.
Leprosy presents a wide range of clinical manifestations determined by the immune response of the individual against the bacillus. Tuberculoid leprosy patients show a response that limits pathogen growth and result in few lesions containing rare (or absence of) bacilli however, nerve damage is often present. Lepromatous leprosy patients are susceptible to disseminated infection. Skin lesions are numerous and there is an uncontrolled proliferation of leprosy bacilli. Such clinical presentations correlate to the level of cell-mediated immunity (CMI) against M. leprae. Antibody responses are greater in lepromatous patients, indicating that humoral immunity does not contribute to host defense .
The delayed-type hypersensitivity reaction (DTH) in skin tests is considered a manifestation of the cell-mediated immunity . In leprosy, cells of M. leprae from different origins and submitted to different processes of purification are the basis for different types of preparations employed in skin tests. Among those preparations, the most frequently used is lepromin, which corresponds to a suspension of heat-killed bacilli . As M. leprae is not cultivated in vitro, cells for lepromin preparation can only be obtained from naturally infected human tissues (lepromas) or from experimentally infected armadillos .
Two types of positive skin reactions are described after the intradermal injection of 0.1 mL of lepromim: an early reaction (Fernandez Reaction), read after 48–72 hours; and a late reaction (Mitsuda Reaction), read after 3–4 weeks . The Mitsuda reaction is measured as induration and provides a measure of the individual’s ability to mount a granulomatous response against mycobacterial antigens . Positive Mitsuda reactions are seen in the vast majority of contacts and unexposed individuals, as well as in tuberculoid leprosy patients; in leprosy patients with lepromatous disease no response is observed. Therefore, reactivity to lepromin can not used for diagnosis, but has a prognostic value . In Brazil, the Centro de Produção e Pesquisa de Imunobiológicos (CPPI) is the only supplier of lepromin antigen for the Brazilian Department of Health, and its production is based on lepromas obtained from lepromatous leprosy patients. This is a difficult process because the production of the antigen depends on access to rare lepromas that may be contaminated with other species of mycobacteria . In addition, the strategy is associated with the risk of manipulation and inoculation of human biological material.
An alternative for replacing whole cells or purified fractions of M. leprae is to use synthetic peptides. Previous studies have demonstrated delayed-type hypersensitivity responses to peptides in skin tests [11, 12]. Aiming at finding alternative diagnostic supplies for leprosy, peptides binding antibody from multibacillary leprosy patients were selected from phage displayed peptide libraries and assessed in their capacity to induce cell response in guinea-pigs sensitized with M. leprae.
The M. tuberculosis H37Rv (ATCC 27294) strain was obtained from the Instituto Adolfo Lutz, São Paulo - Brazil. The cells were grown in Middlebrook 7H10 for 14–21 days at 37°C, followed by suspension in 0.9% NaCl and inactivation at 100°C for 15 minutes. Irradiated M. leprae whole cells isolated from armadillo liver were kindly supplied by Dr. J. S. Spencer from Colorado State University (Fort Collins-USA) through the National Institute of Allergy and Infectious Diseases/National Institutes of Health under contract N01-AI-25469. Bacilli in 0.9% NaCl containing 100 μg/mL phenylmethylsulfonyl fluoride (PMSF) and 2 mM ethylenediaminetetraacetic acid (EDTA) were broken by sonication (Sonopuls HD 2200, Bandelin, Berlin-Germany) four cycles of 15 minutes . Following lysis, the soluble fraction was separated by centrifugation at 10000 × g for 20 minutes at 4°C, and the protein concentration was determined using the Quant-iT Protein Assay kit (Invitrogen, California-USA).
Patient serum samples
Serum samples of 10 paucibacillary patients (PB), 23 multibacillary patients (MB), and 26 household contacts were obtained. The samples were collected at the Hospital de Dermatologia Sanitária (Piraquara, Paraná-Brazil), Centro Regional de Especialidades-Barão (Curitiba, Paraná-Brazil), Fundação Pró-Hansen (Curitiba, Paraná-Brazil), and at Sociedade Filantrópica Humanitas (São Jerônimo da Serra, Paraná-Brazil). Among the leprosy patients, 14 had not yet started the treatment by the time of blood collection, and 19 were under treatment (days - 4 months). Serum of 30 patients with pulmonary tuberculosis (TB) - under treatment (days - 3 months) - was obtained at the Centro Regional de Especialidades-Barão (Curitiba, Paraná-Brazil) and at the Hospital Regional da Lapa ‘São Sebastião’ (Lapa, Paraná-Brazil). Leprosy and TB patients were diagnosed and classified by a specialized physician at the Health Units. Serum of 30 endemic controls was obtained from volunteers with no history of infection by leprosy and tuberculosis. In all cases, drawing of blood was carried out with informed consent and approved by the Research Ethics Committee of Federal University of Paraná (Comitê de Ética em Pesquisa, Setor de Ciências da Saúde, Universidade Federal do Paraná).
Immunoglobulins anti-M. leprae and anti-M. tuberculosis
IgG of the sera pool from MB patients were obtained by precipitation with ammonium sulfate followed by chromatography using protein G-agarose . The anti-M. leprae IgGs were recovered from immunoblots. For that, the M. leprae protein extract was resolved by SDS-PAGE in gradient polyacrylamide gel 10-20%; after having been transferred to the PVDF membrane, IgGs binding antigen immobilized in membrane were eluted with 0.1 M glycine, 0.15 M NaCl, pH 2.8 at room temperature for 30 minutes. Anti-M. leprae IgGs were dialyzed against PBS after neutralization with 1 M Tris–HCl, pH 9.0, and the protein concentration was determined by the Bradford method . The same process was repeated using a sera pool from tuberculosis patients and M. tuberculosis protein in order to obtain anti-M. tuberculosis antibodies.
Screening of random peptide phage display libraries
Linear (X15 and X8CX8) and constrained (XCX4CX and XCX8CX) random peptide libraries were obtained from J. Scott, Simon Fraser University (Burnaby BC-Canada). Peptides are expressed on the surface of protein pVIII of phage f88.4. Two panning strategies were used. In strategy I, the phages of libraries not bound to anti-M. tuberculosis immunoglobulins immobilized in immunotube were used in the first round of panning with anti-M. leprae immunoglobulins. In strategy II, the phages of libraries were directly used in the first round of panning with anti-M. leprae immunoglobulins. Panning was carried out according to the previously given description . Briefly, one immunotube (Nunc, Roskilde-Denmark) was coated with anti-M. leprae immunoglobulin in 100 mM NaHCO3, pH 8.6 at 5 μg/1.5 mL and incubated overnight at 4°C. The immunotube was washed with TBST-0.05% (TBS Tween 20–0.05%), filled with blocking solution (TBST-0.05%, 3% BSA) and incubated for 2 hours at 37°C. For the first round of panning, 1.5 × 1011 phages of libraries X15 and XCX8CX, and 2.5 × 1010 phages of libraries X8CX8 and XCX4CX were incubated in TBST-0.05% with the immobilized antibodies. After the washings with TBST-0.5%, the bound phages were eluted with 1.5 mL 0.1 M glycine, pH 2.2, 1 mg/mL BSA. After neutralization with 2 M Tris–HCl, pH 9.0, the eluted phages were amplified by infecting a culture of E. coli K91. After incubation overnight at 37°C, the supernatant was obtained and precipitated with PEG/NaCl. In the remaining rounds, 2 × 1011 amplified phages of the previous cycle were incubated with IgG anti-M. leprae. The procedures were equal to those applied to the first round except for the fact that the concentration of the antibody immobilized to the immunotube was 1 μg and 0.5 μg in the second and subsequent rounds, respectively.
Immunological screening of phage clones
After four rounds of panning, individual colonies containing phages were picked at random and grown overnight at 37°C in a 96-well microtiter plates in LB medium containing 20 μg/mL tetracycline. The plates were centrifuged (1600 × g, 20 minutes) and supernatant containing phages was analyzed regarding its binding to IgG from leprosy patients by ELISA. Microtiter plates (Falcon, BD Biosciences, California-USA) were coated by incubating 50 μL anti-phage antibody (Sigma-Aldrich, Missouri-USA) diluted 1:800 in 100 mM NaHCO3, pH 8.6, overnight at 4°C. The plates were washed with PBST-0.05% and blocked with 2% skimmed milk powder in PBST-0.05% for 1 hour at 37°C. The supernatant of each phage clone was added to each microtiter well. As a negative control, the supernatant of the E. coli K91 culture was used. After incubation for 2 hours at 37°C, the plate was washed and incubated with 100 μg/mL IgG for 1 hour at 37°C. After washing, peroxidase conjugated anti-human antibody (Sigma-Aldrich, Missouri-USA) - diluted 1:10000 in a blocking solution for 1 hour at 37°C - was added. After washing, bound antibodies were monitored for determining the peroxidase activity using ο-phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich, Missouri-USA) as chromogen for measuring absorbance at 492 nm. The most reactive clones (absorbance at least twice as high as the negative control) were selected for DNA sequencing and subsequent identification of the peptide sequence inserted into the phages.
Determination of peptide sequences
Single-stranded DNA was prepared out of phage clones using QIAprep Spin M13 kit (Qiagen, Hilden-Germany). Peptide sequences of the positive phage clones were determined by the BigDye Terminator v3.1 kit (Applied Biosystems, California-USA) using the reverse primer 5′-TCGGCAAGCTCTTTTAGG-3′.
Reactivity of the phage clones most reactive in the presence of human serum was measured by ELISA according to description given above. Microtiter plates were coated with anti-phage antibody and incubated with 2 × 1010 phages/mL followed by the addition of sera from leprosy patients, tuberculosis patients, household contacts of leprosy patients, and endemic controls, diluted 1:100. The detection of the reaction was performed with peroxidase conjugated anti-human antibody and OPD as chromogen.
Peptides were synthesized using solid phase 9-fluorenilmetoxycarbonyl (Fmoc) chemistry by PepTron (Daejon-Korea). Peptide purity was equal to or higher than 70%.
Guinea pigs and delayed-type hypersensitivity responses
The experiments with these animals followed the guidelines of Brazilian College of Animal Experimentation (Colégio Brasileiro de Experimentação Animal - COBEA) and were approved by the institutional committee of Federal University of Paraná.
Three groups of five 250–300 g outbred female guinea pigs (Cavia porcellus) were used for the skin test. The antigens were diluted in 0.9% NaCl. The Mitsuda lepromin (4x107 bacilli/mL) provided by the Centro de Produção e Pesquisa de Imunobiológicos (Piraquara, Paraná-Brazil) was used as positive control, and 0.9% NaCl was used as negative control. Five animals (group I) were sensitized by subcutaneous inoculation of 200 μg  of M. leprae in Freund’s incomplete adjuvant (Sigma-Aldrich, Missouri-USA). As control, five animals (group II) received 0.9% NaCl in Freund’s incomplete adjuvant subcutaneously. Control group III consisted of non-sensitized animals. After 30 days, each animal received, intradermally, 0.1 mL of the antigens: peptides (10 and 2 μg), peptide pool (10 and 2 μg), Mitsuda lepromin (positive control), soluble extract of M. leprae (10 μg, positive control) and 0.9% NaCl (negative control). The diameter of the skin reaction was measured after 24, 48, and 72 hours, 21 and 28 days.
The peptide sequences were analyzed for sequence similarity using FASTA program on M. leprae sequence data (http://genolist.pasteur.fr/Leproma/).
The phage pool of the last selection round was then chosen to isolate individual positive clones. Each phage clone was assessed – by ELISA – regarding its ability to bind to IgG of multibacillary patients. In strategy I, 24 out of 400 clones analyzed showed recognition against patients’ antibodies, and 6 different peptide sequences were identified. In strategy II, 36 out of the 342 clones were recognized for binding to antibodies against leprosy and all expressed an identical sequence of 15 aminoacids.
Seven phage clones were selected and, among them, clones 5A, and 6A, clones isolated by strategy I, and 1B, clone isolated by strategy II, were detected in a higher number of leprosy patients when compared to the negative controls. Even for the selected clones, a low sensitivity was observed in the detection of leprosy patients. Each serum sample was also tested with wild phage by ELISA in order to evaluate the cross reaction of the serum with the phage without the insert. The results show that the reaction of the phage clones was stronger than that of the wild phage with the positive sera samples against the phage clones (data not shown), indicating that the reactivity happened exclusively between the antibodies and the peptides expressed on the surface of the phages.
Similarity search between peptide sequence and M. leprae sequence database
M. lepraeSanger ID
Secreted antigen 85-B fbpB
Conserved hypothetical protein
Probable protoporhyrinogen oxidase hemK homolog
Possible secreted protease
Possible conserved transmembrane protein
Conserved hypothetical protein
Possible cell cycle protein MesJ
Probable transcriptional regulatory protein WhiB-like whiB4
Conserved hypothetical protein
Probable conserved liproprotein lprD
Probable naphthoate synthase menB
Secreted antigen 85-B fbpB
Probable resuscitation-promoting factor rpfC
Possible conserved transmembrane protein
Possible conserved integral membrane protein
Possible cell cycle protein MesJ
Secreted antigen 85-B fbpB
Secreted antigen 85-A FbpA
Possible RNA methyltransferase
Isoleucyl-tRNA synthetase IleS
2-isopropylmalate synthase leuA
Possible cytochrome C-type biogenesis protein ccsA
Probable conserved Mce associated protein
Conserved hypothetical protein
Conserved hypothetical protein
Conserved hypothetical protein
Conserved hypothetical protein
The lack of cellular response in other animals is probably due to the influence of genetic factors involving genes MHC in the responses to peptides [11, 23]. Thus, the mixture of peptides able to recognize different forms of disease or different genetic aspects could help to overcome problems of genetic restriction to individual peptides. Other factors that need to be evaluated are the dosage and the constitution of the antigen as, for example, the conjugation with proteins or modification of the peptide structure. Differences were found in the DTH response regarding the dosage of the inoculated peptide [11, 24]. Other studies have tested peptides in the form of peptide-protein conjugation proteins  or as peptides modified by the addition of fatty acids and acetylation .
Differences in reactivity between phage clones and the corresponding free peptide have been described previously [27, 28]. When in phage, the sequence could to assume a favorable position to act as binder of antibodies  and therefore this conformation could disappear when used as synthetic peptides. Likewise, the conformation of the peptide expressed on the phage surface may discourage recognition by antibodies. Thus, other peptide sequences identified but not included in DTH tests will be evaluated in future studies. The decision was to limit the tests to the phage clones that were reactive with larger number of patients. The selection of mimotopes was based on seroreactivity and therefore these mimetic peptides correspond to B cell epitopes. The strategy of the study was to test whether these peptides would be able to act as T cell epitopes. Serological and cellular assays, as proposed initiated this study may determine whether a peptide can comprise a serological or T cell test reagent. Tests for humoral immune response benefit lepromatous patients while tests for evaluation of cellular response will aid in the diagnosis of tuberculoid patients.
Lepromin is probably the only skin test antigen that reflects the individual’s ability to generate a granulomatous response to mycobacterial antigens, as opposed to the 48–72 hours delayed-type hypersensitivity response found with tuberculin and other skin tests . In the lepromin test, the Fernandez reaction is similar to the reaction produced by tuberculin, since it assesses the delayed-type hypersentivity of the individual to M. leprae soluble antigens . In this aspect, the present study proposes the use of peptides in skin tests to assess the cellular response, similar to the one captured by the Mantoux test used in tuberculosis. Besides in vivo studies, the peptides identified can be assessed in the future regarding their ability to induce INF-γ production by peripheral blood mononuclear cells of patients, aiming to verify whether those reagents allow the detection of the paucibacillary disease. However, the skin tests are more feasible and useful as compared to INF-γ production assays, since the latter is dependent on the access to advanced lab facilities and trained personnel, which limits its use in countries with limited resources , a proposal advocated in the present study. Recently, the development of a user-friendly assay to detect multiple cytokines  which can make INF-γ detection assays more accessible and easier to perform was reported.
Synthetic peptides prove to be very attractive to be used in diagnostic tests or for monitoring the degree of exposure to leprosy within different communities, or even an adjunct to leprosy control programs , since they are easy to produce with reproducibility, as well as high quality and purity control . In addition, synthetic peptides can be easily obtained at a low production cost through chemical synthesis. Comparatively, crude antigens originating from M. leprae are complex mixtures that carry proteins of humans or animal tissues in their composition, which may pose biological risks.
Peptides mimotopes were isolated from phage displayed libraries by screening purified antibodies derived from leprosy patients’ sera. Our strategy was to evaluate the ability of mimotopes to induce cellular response in DTH tests. The selected sets of peptides are also a starting point to the future design of more effective reagents for diagnostic purposes.
We would like to thank the representatives and members of the Hospital de Dermatologia Sanitária do Paraná, the Centro Regional de Especialidades-Barão,the Sociedade Filantrópica Humanitas, the Hospital Regional da Lapa São Sebastião, and the Fundação Pró-Hansen for giving us access to their facilities in order to collect samples from patients. We also thank the Centro de Produção e Pesquisa de Imunobiológicos for their cooperation; Dr. John Spencer, University of Colorado, for providing the M. leprae cells; Dr Jamie K.Scott, Simon Fraser University, for having provided the peptides libraries displayed in phages. The present research was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). S.M.A. was supported by funds granted by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior- Ministry of Education - Brazil). The authors would like to thank Dr Carlos Chávez Olórtegui for providing the wild phage.
- Britton WJ, Lockwood DNJ: Leprosy. Lancet. 2004, 363: 1209-1219. 10.1016/S0140-6736(04)15952-7.View ArticlePubMedGoogle Scholar
- Stefani MM: Challenges in the post genomic era for the development of tests for leprosy diagnosis. Rev Soc Bras Med Trop. 2008, 43 (Suppl 2): 89-94.View ArticleGoogle Scholar
- Bührer-Sékula S: Sorologia PGL-I na hanseníase. Rev Soc Bras Med Trop. 2008, 41 (Suppl 2): 3-5.View ArticlePubMedGoogle Scholar
- WHO: Global leprosy situation. 2010, http://www.who.int/wer/2010/wer8535.pdf,Google Scholar
- Geluk A, van der Ploeg J, Teles RO, Franken KL, Prins C, Drijfhout JW, Sarno EN, Sampaio EP, Ottenhoff TH: Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection. Clin Vaccine Immunol. 2008, 15: 522-533. 10.1128/CVI.00432-07.View ArticlePubMedPubMed CentralGoogle Scholar
- Modlin RL: The innate immune response in leprosy. Curr Opin Immunol. 2010, 22: 48-54. 10.1016/j.coi.2009.12.001.View ArticlePubMedPubMed CentralGoogle Scholar
- Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL: The continuing challenges of leprosy. Clin Microbiol Rev. 2006, 19: 338-381. 10.1128/CMR.19.2.338-381.2006.View ArticlePubMedPubMed CentralGoogle Scholar
- WHO: Recommended safety requirements for the preparation of lepromin: a WHO Memorandum. Bull World Health Organ. 1979, 57: 921-923.Google Scholar
- Hastings RC, Gillis TP, Krahenbuhl JL, Franzblau SG: Leprosy. Clin Microbiol Rev. 1988, 1: 330-348.View ArticlePubMedPubMed CentralGoogle Scholar
- Alban SM, Sella SRBR, Miranda RN, Mira MT, Thomaz-Soccol V: PCR-Restriction Fragment Length Polymorphism analysis as a tool for Mycobacterium species identification in lepromas for lepromin production. Lepr Rev. 2009, 80: 129-142.PubMedGoogle Scholar
- Estrada IC, Gutiérrez MC, Esparza J, Quesada-Pascual F, Estrada-Parra S, Possani LD: Use of synthetic peptides corresponding to sequences of Mycobacterium leprae proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Int J Lepr Other Mycobact Dis. 1992, 60: 18-27.PubMedGoogle Scholar
- Aaggard C, Brock I, Olsen A, Ottenhoff TH, Weldingh K, Andersen P: Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis. 2004, 189: 812-819. 10.1086/381679.View ArticleGoogle Scholar
- Pessolani MC, Brennan PJ: Mycobacterium leprae produces extracellular homologs of the antigen 85 complex. Infect Immun. 1992, 60: 4452-4459.PubMedPubMed CentralGoogle Scholar
- Harlow E, Lane D: Antibodies: A Laboratory Manual. 1988, Cold Spring Harbor Laboratory, New YorkGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.View ArticlePubMedGoogle Scholar
- Villard S, Lacroix-Desmazes S, Kieber-Emmons T, Piquer D, Grailly S, Benhida A, Kaveri SV, Saint-Remy JM, Granier C: Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood. 2003, 102: 949-952. 10.1182/blood-2002-06-1886.View ArticlePubMedGoogle Scholar
- Melancon-Kaplan J, Hunter SW, McNeil M, Stewart C, Modlin RL, Rea TH, Convit J, Salgame P, Mehra V, Bloom BR, Brennan PJ: Immunological significance of Mycobacterium leprae cell walls. Proc Natl Acad Sci USA. 1998, 85: 1917-1921.View ArticleGoogle Scholar
- Gaylord H, Brennan PJ: Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease. Ann Rev Microbiol. 1987, 41: 645-675. 10.1146/annurev.mi.41.100187.003241.View ArticleGoogle Scholar
- Li Y, Ning Y, Wang Y, Peng D, Jiang Y, Zhang L, Long M, Luo J, Li M: Mimotopes selected with a neutralizing antibody against urease B from Helicobacter pylori induce enzyme inhibitory antibodies in mice upon vaccination. BMC Biotechnol. 2010, 10 (30): 84-View ArticlePubMedPubMed CentralGoogle Scholar
- Mehra V, Bloom BR: Induction of cell-mediated immunity to Mycobacterium leprae in guinea pigs. Infect Immun. 1979, 23: 787-794.PubMedPubMed CentralGoogle Scholar
- Mehra V, Bloom BR, Bajardi AC, Grisso CL, Sieling PA, Alland D, Convit J, Fan XD, Hunter SW, Brennan PJ, Rea TH, Modlin RL: A major T cell antigen of Mycobacterium leprae is a 10-KD heat-shock cognate protein. J Exp Med. 1992, 175: 275-284. 10.1084/jem.175.1.275.View ArticlePubMedGoogle Scholar
- Brennan PJ: Skin test development in leprosy: progress with first-generation skin test antigens, and an approach to the second generation. Lepr Rev. 2000, 71 (Suppl): S50-S54.PubMedGoogle Scholar
- Mackall JC, Bai GH, Rouse DA, Armoa GR, Chuidian F, Nair J, Morris SL: A comparison of the T cell delayed-type hypersensitivity epitopes of the 19-kD antigens from Mycobacterium tuberculosis and Myco. intracellulare using overlapping synthetic peptides. Clin Exp Immunol. 1993, 93: 172-177.View ArticlePubMedPubMed CentralGoogle Scholar
- Sitz KV, Loomis-Price LD, Ratto-Kim S, Kenner JR, Sau P, Eckels KH, Redfield RR, Birx DL: Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. J Infect Dis. 1997, 176: 1085-1089. 10.1086/516517.View ArticlePubMedGoogle Scholar
- Kel JM, de Geus ED, van Stipdonk MJ, Drijfhout JW, Koning F, Nagelkerken L: Immunization with mannosylated peptide induces poor T cell effector functions despite enhanced antigen presentation. Int Immunol. 2008, 20: 117-127.View ArticlePubMedGoogle Scholar
- Oettinger T, Holm A, Haslov K: Characterization of the delayed type hypersensitivity-inducing epitope of MPT64 from Mycobacterium tuberculosis. Scand J Immunol. 1997, 45: 499-503. 10.1046/j.1365-3083.1997.d01-429.x.View ArticlePubMedGoogle Scholar
- Minenkova O, Gargano N, De Tomassi A, Bellintani F, Pucci A, Fortugno P, Fuscaldi E, Pessi A, Rapicetta M, Miceli M, Iundicone P, Cortese R, Felici F, Monaci P: ADAM-HCV, a new-concept diagnostic assay for antibodies to hepatitis C virus in serum. Eur J Biochem. 2001, 268: 4758-4768. 10.1046/j.1432-1327.2001.02402.x.View ArticlePubMedGoogle Scholar
- Van Nieuwenhove L, Büscher P, Balharbi F, Humbert M, Dieltjens T, Guisez Y, Lejon V: Identification of mimotopes with diagnostic potential for Trypanosoma brucei gambiense variant surface glycoproteins using human antibody fractions. PLoS Negl Trop Dis. 2012, 6: e1682-10.1371/journal.pntd.0001682.View ArticlePubMedPubMed CentralGoogle Scholar
- Kishchenko G, Batliwala H, Makowski L: Structure of a foreign peptide displayed on the surface of bacteriophage M13. J Mol Biol. 1994, 241: 208-213. 10.1006/jmbi.1994.1489.View ArticlePubMedGoogle Scholar
- Lillebaek T, Bergstedt W, Tingskov PN, Thierry-Carstensen B, Aggerbeck H, Hoff ST, Weldingh K, Andersen P, Soborg B, Thomsen VO, Andersen AB: Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique. Tuberculosis. 2009, 89: 158-162. 10.1016/j.tube.2008.09.007.View ArticlePubMedGoogle Scholar
- Corstjens PL, de Dood CJ, van der Ploeg-van Schip JJ, Wiesmeijer KC, Riuttamäki T, van Meijgaarden KE, Spencer JS, Tanke HJ, Ottenhoff TH, Geluk A: Lateral flow assay for simultaneous detection of cellular-and humoral immune responses. Clin Biochem. 2011, 44: 1241-1246. 10.1016/j.clinbiochem.2011.06.983.View ArticlePubMedPubMed CentralGoogle Scholar
- Dockrell HM, Brahmbhatt S, Robertson BD, Britton S, Fruth U, Gebre N, Hunegnaw M, Hussain R, Manandhar R, Murillo L, Pessolani MC, Roche P, Salgado JL, Sampaio E, Shahid F, Thole JE, Young DB: A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents. Infect Immun. 2000, 68: 5846-5855. 10.1128/IAI.68.10.5846-5855.2000.View ArticlePubMedPubMed CentralGoogle Scholar
- Aráoz R, Honoré N, Banu S, Demangel C, Cissoko Y, Arama C, Uddin MK, Hadi SK, Monot M, Cho SN, Ji B, Brennan PJ, Sow S, Cole ST: Towards an immunodiagnostic test for leprosy. Microbes Infect. 2006, 8: 2270-2276. 10.1016/j.micinf.2006.04.002.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/42/prepub